Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks

BackgroundThis study examines the risks of hypertension and thrombotic events in NSCLC patients treated with Tyrosine Kinase Inhibitors (TKIs).ObjectiveTo compare the safety profiles of TKIs used in NSCLC treatment, focusing on hypertension and thrombotic risks.MethodsA comprehensive search identifi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mingming Tan, Chenwei Pu, Zhenzhen Wang, Chengwei Jin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Pharmacology
Subjects:	non-small cell lung cancer tyrosine kinase inhibitors hypertension thrombotic events network meta-analysis NSCLC
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1491990/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
by: Jia-Jun Wu, MD, et al.
Published: (2025-06-01)

Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: a systematic review and meta-analysis
by: Hengyu Tian, et al.
Published: (2025-04-01)

Novel Insights Into Receptor Tyrosine Kinases in Pulmonary Arterial Hypertension
by: Wenze Wu, et al.
Published: (2025-08-01)

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia
by: IL Davydkin, et al.
Published: (2018-10-01)

The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer
by: Faris Alrumaihi, et al.
Published: (2025-06-01)

Incidence Status and Factors Associated With Tyrosine Kinase Inhibitor‐Induced Hypertension in Patients With Renal Cell Carcinoma
by: Satoru Nakanishi, et al.
Published: (2025-05-01)

Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors
by: Nikhil Vojjala, et al.
Published: (2025-01-01)

Establishment of in vitro Src tyrosine kinase inhibitors screening model
by: WANG Chen-hui, et al.
Published: (2007-11-01)

MED12 mutation induces RTK inhibitor resistance in NSCLC via MEK/ERK pathway activation by inflammatory cytokines
by: Hyun-Min Ryu, et al.
Published: (2025-08-01)

Advancing endometrial cancer treatment: exploring immunotherapy and tyrosine kinase inhibitors through clinical cases
by: Vanda Salutari
Published: (2025-06-01)

The effectiveness of tyrosine kinase inhibitor for chronic myeloid leukemia in tuberous sclerosis. A case report and review of literature
by: Abdulrahman Al‐Abdulmalek, et al.
Published: (2023-03-01)

Efficacy and safety of tyrosine kinase inhibitors with thoracic radiotherapy for patients with oncogene-mutated non-small cell lung cancer: a meta-analysis
by: Wenxia Li, et al.
Published: (2024-11-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
by: Maria Dimou, et al.
Published: (2014-01-01)

Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis
by: Chang X, et al.
Published: (2025-03-01)

Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor After Imatinib Resistance
by: Xian-Hao Xiao, et al.
Published: (2025-07-01)

Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes
by: Meng Zhang, et al.
Published: (2025-08-01)

Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors
by: GA Gusarova, et al.
Published: (2016-10-01)

EGFR Mutation as a Predictive Factor to Treatment Response of TKI (Tyrosine Kinase Inhibitor) in Non-Small Cell Lung Cancer Stage 4: A Case Report
by: Wulyo Rajabto, et al.
Published: (2021-03-01)

Transformation of adenocarcinoma into small cell lung cancer as one of the mechanisms of acquired resistance to anti-EGFR tyrosine kinase inhibitors
by: O. O. Kovalov, et al.
Published: (2024-04-01)

A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors based on FAERS database
by: Zongwei Tang, et al.
Published: (2025-07-01)

Dose Optimization of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
by: Chen J, et al.
Published: (2025-07-01)

Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
by: O. Y. Vinogradova
Published: (2015-10-01)

Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)
by: Qingjian He, et al.
Published: (2025-01-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01)

Exploring research frontiers and emerging trends of tyrosine kinase inhibitors in the treatment of colorectal cancer
by: Xiaosong Li, et al.
Published: (2025-07-01)

Food interactions with tyrosine kinase inhibitors used to treat advanced renal cell carcinoma
by: Agata Sałek-Zań, et al.
Published: (2025-03-01)

Physiologically Based Pharmacokinetic Model of Tyrosine Kinase Inhibitors to Predict Target Site Penetration, with PET‐Guided Verification
by: Suzanne van derGaag, et al.
Published: (2025-05-01)

Epithelial–mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC)
by: Ma. Carmela P. Dela Cruz, et al.
Published: (2025-05-01)

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

Transarterial chemoembolization combined with tyrosine kinase inhibitors and/or immune checkpoint inhibitors induced hypothyroidism is associated with improved overall survival in hepatocellular carcinoma
by: Shengyuan Xu, et al.
Published: (2025-05-01)

Neddylation status determines the therapeutic sensitivity of tyrosine kinase inhibitors in chronic myeloid leukemia
by: Congyi Zhang, et al.
Published: (2025-05-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

Design, Docking Analysis, and Structure–Activity Relationship of Ferrocene-Modified Tyrosine Kinase Inhibitors: Insights into BCR-ABL Interactions
by: Irena Philipova, et al.
Published: (2025-07-01)

Chronic Myelogenous Leukemia Patients on Tyrosine Kinase Inhibitors—Hematological Changes and Correlation with European Leukemia Network Response Criteria
by: Karthik Bommannan, et al.

Anti-angiogenic tyrosine kinase inhibitors and the pathophysiology of their toxic effects: revisiting the treatment of anemia in metastatic cancers
by: Tai Van Nguyen, et al.
Published: (2025-04-01)

Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
by: S. I. Kutsev, et al.
Published: (2022-11-01)

Tyrosine kinase inhibitors modulate the expression of peroxiredoxins 1 and 2 in chronic myeloid leukemia cells
by: Hiroshi Kazama, et al.
Published: (2025-01-01)

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases
by: Nozomi Sasaki, et al.
Published: (2025-01-01)

Salvage Pulmonary Resection After Immune Checkpoint or Tyrosine Kinase Inhibitor Therapy for Initially Unresectable Non-Small-Cell Lung Cancer: A Systematic Review
by: Vasile Gaborean, et al.
Published: (2025-06-01)